{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:35:50Z","timestamp":1791923750120,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The goal of this Phase I\/II trial is to assess the safety and efficacy of administering durvalumab concurrent with weekly nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide (ddAC) neoadjuvant therapy for stages I\u2013III triple-negative breast cancer. The primary endpoint is pathologic complete response (pCR:ypT0\/is, ypN0). The response was correlated with PDL1 expression and stromal tumor-infiltrating lymphocytes (sTILs). Two dose levels of durvalumab (3 and 10\u2009mg\/kg) were assessed. PD-L1 was assessed using the SP263 antibody; \u22651% immune and tumor cell staining was considered positive; sTILs were calculated as the area occupied by mononuclear inflammatory cells over the total intratumoral stromal area. 59 patients were evaluable for toxicity and 55 for efficacy in the Phase II study (10\u2009mg\/kg dose). No dose-limiting toxicities were observed in Phase I. In Phase II, pCR rate was 44% (95% CI: 30\u201357%); 18 patients (31%) experienced grade 3\/4 treatment-related adverse events (AE), most frequently neutropenia (<jats:italic>n<\/jats:italic>\u2009=\u20094) and anemia (<jats:italic>n<\/jats:italic>\u2009=\u20094). Immune-related grade 3\/4 AEs included Guillain\u2013Barre syndrome (<jats:italic>n<\/jats:italic>\u2009=\u20091), colitis (<jats:italic>n<\/jats:italic>\u2009=\u20092), and hyperglycemia (<jats:italic>n<\/jats:italic>\u2009=\u20092). Of the 50 evaluable patients for PD-L1, 31 (62%) were PD-L1 positive. pCR rates were 55% (95% CI: 0.38\u20130.71) and 32% (95% CI: 0.12\u20130.56) in the PD-L1 positive and negative groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.15), respectively. sTIL counts were available on 52 patients and were significantly higher in the pCR group (<jats:italic>p<\/jats:italic>\u2009=\u20090.0167). Concomitant administration of durvalumab with sequential weekly nab-paclitaxel and ddAC neoadjuvant chemotherapy resulted in a pCR rate of 44%; pCR rates were higher in sTIL-high cancers.<\/jats:p>","DOI":"10.1038\/s41523-021-00219-7","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:31:35Z","timestamp":1612819895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in triple-negative breast cancer"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7504-867X","authenticated-orcid":false,"given":"Julia","family":"Foldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Silber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-6538","authenticated-orcid":false,"given":"Emily","family":"Reisenbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaljeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Persico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerin","family":"Adelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika","family":"Katoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees","family":"Chagpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristen","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2508-5736","authenticated-orcid":false,"given":"Michal","family":"Marczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Burrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-6540","authenticated-orcid":false,"given":"Eiman","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalai","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Blenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4397","authenticated-orcid":false,"given":"David L.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-6686","authenticated-orcid":false,"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"219_CR1","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams, S. et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32, 2959\u20132966 (2014).","journal-title":"J. Clin. Oncol."},{"key":"219_CR2","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1200\/JCO.2009.27.2419","volume":"28","author":"G Bianchini","year":"2010","unstructured":"Bianchini, G. et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J. Clin. Oncol. 28, 4316\u20134323 (2010).","journal-title":"J. Clin. Oncol."},{"key":"219_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105\u2013113 (2010).","journal-title":"J. Clin. Oncol."},{"key":"219_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci, L., Schiavoni, G., Sistigu, A. & Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21, 15\u201325 (2014).","journal-title":"Cell Death Differ."},{"key":"219_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301\u20131309 (2014).","journal-title":"Nat. Med."},{"key":"219_CR6","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","volume":"20","author":"KA Schalper","year":"2014","unstructured":"Schalper, K. A. et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin. Cancer Res. 20, 2773\u20132782 (2014).","journal-title":"Clin. Cancer Res."},{"key":"219_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf, E. A. et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2, 361\u2013370 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"219_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","volume":"3","author":"H Wimberly","year":"2015","unstructured":"Wimberly, H. et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol. Res. 3, 326\u2013332 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"219_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1158\/1535-7163.MCT-17-1005","volume":"17","author":"V Pelekanou","year":"2018","unstructured":"Pelekanou, V. et al. Tumor-infiltrating lymphocytes and PD-L1 expression in pre- and posttreatment breast cancers in the SWOG S0800 phase II neoadjuvant chemotherapy trial. Mol. Cancer Ther. 17, 1324\u20131331 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"219_CR10","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart, R. et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol. Res. 3, 1052\u20131062 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"219_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-016-3889-6","volume":"158","author":"ZA Nahleh","year":"2016","unstructured":"Nahleh, Z. A. et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res. Treat. 158, 485\u2013495 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"219_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","volume":"17","author":"M Untch","year":"2016","unstructured":"Untch, M. et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 17, 345\u2013356 (2016).","journal-title":"Lancet Oncol."},{"key":"219_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/OTT.S122974","volume":"10","author":"HH Soliman","year":"2016","unstructured":"Soliman, H. H. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. OncoTargets Ther. 10, 101\u2013112 (2016).","journal-title":"OncoTargets Ther."},{"key":"219_CR14","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.1158\/1078-0432.CCR-20-1303","volume":"26","author":"FS Ahmed","year":"2020","unstructured":"Ahmed, F. S. et al. PD-L1 Protein expression on both tumor cells and macrophages are associatedwith response to neoadjuvant durvalumab with chemotherapy in triplenegative breast cancer. Clin. Cancer Res. 26, 5456\u20135461 (2020).","journal-title":"Clin. Cancer Res."},{"key":"219_CR15","first-page":"52","volume":"7","author":"N McAndrew","year":"2018","unstructured":"McAndrew, N. & DeMichele, A. Neoadjuvant chemotherapy considerations in triple-negative breast cancer. J. Target Ther. Cancer 7, 52\u201369 (2018).","journal-title":"J. Target Ther. Cancer"},{"key":"219_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl, S. et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. J. Eur. Soc. Med. Oncol. 30, 1279\u20131288 (2019).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"219_CR17","doi-asserted-by":"crossref","unstructured":"Pusztai, L. et al. Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II\/III breast cancer: results from the I-SPY 2 TRIAL. in Proc. 111th Annual Meeting of the American Association for Cancer Research vol. Abstract nr CT-011 (AACR, 2020).","DOI":"10.1158\/1538-7445.AM2020-CT011"},{"key":"219_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative. Breast Cancer N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"Breast Cancer N. Engl. J. Med."},{"key":"219_CR19","doi-asserted-by":"crossref","unstructured":"Nanda, R. et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6, 676\u2013684 (2020).","DOI":"10.1001\/jamaoncol.2019.6650"},{"key":"219_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090\u20131100 (2020).","journal-title":"Lancet"},{"key":"219_CR21","doi-asserted-by":"crossref","unstructured":"Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res. 80, Abstract no. GS3-04 (2020).","DOI":"10.1158\/1538-7445.SABCS19-GS3-04"},{"key":"219_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"219_CR23","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"219_CR24","doi-asserted-by":"publisher","first-page":"v859","DOI":"10.1093\/annonc\/mdz394.010","volume":"30","author":"J Cort\u00e9s","year":"2019","unstructured":"Cort\u00e9s, J. et al. LBA21 - KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann. Oncol. 30, v859\u2013v860 (2019).","journal-title":"Ann. Oncol."},{"key":"219_CR25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2020.38.15_suppl.1000","volume":"38","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J. Clin. Oncol. 38, 1000 (2020).","journal-title":"J. Clin. Oncol."},{"key":"219_CR26","doi-asserted-by":"crossref","unstructured":"Dalenc, F. et al. Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: results from phase II randomized trial SAFIR02-IMMUNO. Cancer Res. 80, GS3-02 (2020).","DOI":"10.1158\/1538-7445.SABCS19-GS3-02"},{"key":"219_CR27","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/annonc\/mdy399","volume":"29","author":"B Szekely","year":"2018","unstructured":"Szekely, B. et al. Immunological differences between primary and metastatic breast cancer. Ann. Oncol. J. Eur. Soc. Med. Oncol. 29, 2232\u20132239 (2018).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"219_CR28","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.humpath.2013.03.010","volume":"44","author":"A Cimino-Mathews","year":"2013","unstructured":"Cimino-Mathews, A., Ye, X., Meeker, A., Argani, P. & Emens, L. A. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum. Pathol. 44, 2055\u20132063 (2013).","journal-title":"Hum. Pathol."},{"key":"219_CR29","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/cas.13101","volume":"107","author":"R Ogiya","year":"2016","unstructured":"Ogiya, R. et al. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 107, 1730\u20131735 (2016).","journal-title":"Cancer Sci."},{"key":"219_CR30","doi-asserted-by":"crossref","unstructured":"McNeill, C. J., Fehmi, J., Gladwin, J. & Price, C. A rare case of Miller Fisher variant of Guillain-Barr\u00e9 Syndrome (GBS) induced by a checkpoint inhibitor. BMJ Case Rep. 12, e229443 (2019).","DOI":"10.1136\/bcr-2019-229443"},{"key":"219_CR31","first-page":"552","volume":"17","author":"ML Telli","year":"2019","unstructured":"Telli, M. L., Gradishar, W. J. & Ward, J. H. NCCN guidelines updates: breast. Cancer J. Natl Compr. Cancer Netw. 17, 552\u2013555 (2019).","journal-title":"Cancer J. Natl Compr. Cancer Netw."},{"key":"219_CR32","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans, W. F. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 25, 4414\u20134422 (2007).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"219_CR33","doi-asserted-by":"publisher","unstructured":"Foldi, J. et al. Metadata record for the manuscript: single arm neoadjuvant Phase I\/II study of durvalumab plus weekly nab-paclitaxel and dose dense doxorubicin\/cyclophosphamide for stage I-III triple negative breast cancer. figshare https:\/\/doi.org\/10.6084\/m9.figshare.13362968 (2020).","DOI":"10.6084\/m9.figshare.13362968"}],"updated-by":[{"DOI":"10.1038\/s41523-022-00392-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000}}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-021-00219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-021-00219-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-021-00219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T20:12:55Z","timestamp":1670011975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-021-00219-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1038\/s41523-021-00219-7","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41523-022-00392-3","asserted-by":"object"}]},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41523-022-00392-3","URL":"https:\/\/doi.org\/10.1038\/s41523-022-00392-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S. has received honoraria and consulting fees from Astra Zeneca. D.L.R. has served as an advisor and consultant for Amgen, Astra Zeneca, Biocept, BMS, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, Konica\/Minolta, Merck, NanoString, NextCure, Odonate, Perkin Elmer, PAIGE.AI, Roche, Sanofi, Ventana, and Ultivue; received research funding from Amgen, Cepheid, NavigateBP, NextCure, Konica\/Minolta, Lilly, and Ultivue; received instrument support from Akoya\/Perkin Elmer, NanoString and Ventana; is a founder and equity holder of PixelGear, and received royalties from Rarecyte. L.P. has received consulting fees and honoraria from Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio, and Daiichi. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}